Details of Disease

General Information of Disease (ID: DIST2R60)

Disease Name Malignant pleural mesothelioma
Synonyms pleura mesothelioma; pleural diffuse malignant mesothelioma; pleural malignant mesothelioma; malignant mesothelioma of the pleura; malignant mesothelioma of pleura; malignant pleural mesothelioma
Disease Class 2C26: Pleural mesothelioma
Definition
A malignant neoplasm that arises from mesothelial cells in the pleura and shows a diffuse growth pattern. It arises on the parietal and sometimes visceral pleura as multiple small nodules that later become confluent and invade the chest wall adipose tissue and muscle. Asbestos exposure is the main cause for the development of pleural malignant mesothelioma. It usually affects patients over sixty years of age. The latency period is long. Patients usually present with pleural effusion, dyspnea and chest wall pain. Additional signs and symptoms include chills, sweating, weight loss, and weakness. Morphologic variants include epithelioid, desmoplastic, sarcomatoid, and biphasic mesothelioma. The clinical course is usually aggressive.
Disease Hierarchy
DISTHJGH: Malignant mesothelioma
DISTTZOD: Pleural mesothelioma
DISKWK9M: Mesothelioma
DISPEAWB: Pleural cancer
DIST2R60: Malignant pleural mesothelioma
ICD Code
ICD-11
ICD-11: 2C26.0
ICD-9
ICD-9: 163
Expand ICD-11
'2C26.0
Expand ICD-10
'C45-C49; 'C45; 'C45.0; 'C45.7
Expand ICD-9
163
Disease Identifiers
MONDO ID
MONDO_0005112
MESH ID
D000086002
UMLS CUI
C0812413
MedGen ID
208810
HPO ID
HP:0100002
SNOMED CT ID
254645002

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 2 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Nivolumab DMAB9QE Approved Monoclonal antibody [1]
Pemetrexed DMMX2E6 Approved Small molecular drug [2]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Galinpepimut-S DMTEQEQ Phase 3 NA [1]
NGR-hTNF DM3PZLM Phase 3 NA [3]
Anetumab ravtansine DMKFRWU Phase 2 Antibody drug conjugate [1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 39 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ATIC TT9NVXQ Limited Altered Expression [4]
BIRC7 TTHZ8TA Limited Altered Expression [5]
CD4 TTN2JFW Limited Biomarker [6]
CLIC1 TT8KZG6 Limited Altered Expression [7]
DCLK3 TTMYK4Z Limited Altered Expression [8]
DPP10 TTOVUPC Limited Altered Expression [9]
EGFL7 TT7WD0H Limited Posttranslational Modification [10]
EPHA2 TTRJB2G Limited Biomarker [11]
EPX TTCIO0M Limited Biomarker [12]
FECH TTQ6VF4 Limited Biomarker [12]
FOLR1 TTVC37M Limited Altered Expression [13]
GUCY2D TTWNFC2 Limited Altered Expression [14]
KDM6B TTDIJUQ Limited Altered Expression [15]
KIF11 TTBGTCW Limited Biomarker [16]
KRT19 TT3JF9E Limited Biomarker [17]
LAG3 TTNVXAW Limited Biomarker [6]
MCAM TTHRE05 Limited Biomarker [18]
MTAP TTDBX7N Limited Altered Expression [19]
NAGLU TTDM6HZ Limited Altered Expression [20]
RTN4R TTVRZUO Limited Biomarker [21]
TBXAS1 TTKNWZ4 Limited Altered Expression [22]
TUSC2 TTJ8O14 Limited Biomarker [23]
AQP1 TTSF1KH Strong Altered Expression [24]
BIRC3 TTAIWZN Strong Altered Expression [25]
CD74 TTCMYP9 Strong Biomarker [26]
DPP4 TTDIGC1 Strong Biomarker [27]
GHRHR TTG4R8V Strong Biomarker [28]
MDM2 TT9TE0O Strong Biomarker [29]
MSLN TT4RXME Strong Altered Expression [30]
MTNR1A TT0WAIE Strong Biomarker [31]
MTNR1B TT32JK8 Strong Biomarker [31]
SLC46A1 TTY8Z2E Strong Biomarker [32]
SLC52A2 TT6TKEN Strong Biomarker [33]
SOCS1 TT8COJM Strong Altered Expression [34]
SP1 TTZEP6S Strong Biomarker [35]
SRGN TTCHB06 Strong Altered Expression [36]
TMPRSS6 TTL9KE7 Strong Biomarker [31]
TYMS TTP1UKZ Strong Altered Expression [37]
GART TTEXB9Z Definitive Altered Expression [38]
------------------------------------------------------------------------------------
⏷ Show the Full List of 39 DTT(s)
This Disease Is Related to 3 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
ABCC5 DTYVM24 Limited Genetic Variation [39]
SLC25A16 DTNU9EW Limited Biomarker [40]
ABCB5 DTKVEXO Definitive Biomarker [41]
------------------------------------------------------------------------------------
This Disease Is Related to 1 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
ALDH1A2 DEKN1H4 Limited Altered Expression [42]
------------------------------------------------------------------------------------
This Disease Is Related to 65 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ACACA OT5CQPZY Limited Biomarker [43]
ALDH1A3 OT1C9NKQ Limited Altered Expression [44]
BBS1 OTXSXB1K Limited Altered Expression [45]
BIN1 OTK8O0X8 Limited Altered Expression [46]
BMS1 OTEGQ8ZO Limited Biomarker [43]
CACUL1 OT6P1ZVP Limited Biomarker [47]
CCDC6 OTXRQDYG Limited Biomarker [48]
CLDN15 OT9K0KI7 Limited Altered Expression [49]
CLDN3 OT71MN9S Limited Biomarker [50]
CLIC3 OT5KUZ3A Limited Altered Expression [7]
CLIC4 OT6KTPKD Limited Altered Expression [7]
CLTA OTLHOXMQ Limited Altered Expression [14]
CUL1 OTXPE1UZ Limited Biomarker [51]
DDB2 OTO8HVVB Limited Biomarker [52]
DDX51 OTLMA7AH Limited Biomarker [53]
DNAJA1 OT38BZQQ Limited Biomarker [23]
EID1 OT3OI5H4 Limited Altered Expression [54]
EMX2 OT0V8OYK Limited Altered Expression [55]
FOXK1 OTLZGS7J Limited Genetic Variation [56]
IFNA17 OTHXRYG3 Limited Genetic Variation [57]
ITGA7 OTTBTAYW Limited Posttranslational Modification [58]
KAZALD1 OTSFOX2H Limited Biomarker [59]
KIF23 OTY850JC Limited Biomarker [16]
MAPK13 OT0W9GE7 Limited Biomarker [59]
MTA2 OTCCYIQJ Limited Altered Expression [45]
MYO18B OTGYY4NK Limited Biomarker [60]
MYO1A OTS80FOD Limited Altered Expression [61]
NBAS OTW9IBRI Limited Altered Expression [20]
NDC80 OTS7D306 Limited Biomarker [62]
PKP3 OTPL1HRB Limited Altered Expression [63]
PLXNA1 OTN0BING Limited Biomarker [64]
PPRC1 OT6GB3WR Limited Altered Expression [65]
PROCR OTRHED17 Limited Biomarker [66]
RAD23B OT0PGOG3 Limited Biomarker [67]
RAMP2 OTGQXLH5 Limited Altered Expression [8]
RAMP3 OTX6XLLM Limited Altered Expression [8]
RASSF5 OT6Q41I2 Limited Biomarker [68]
SCN7A OTK05PXY Limited Altered Expression [20]
SEMA3C OTEGUY7F Limited Altered Expression [69]
SEMA6D OTU0UAZS Limited Altered Expression [64]
SIM2 OT0QWHK4 Limited Biomarker [70]
SMG1 OTTS3SXE Limited Altered Expression [71]
TNIP1 OTRAOTEW Limited Biomarker [72]
ALG1 OTVXPA9E Strong Biomarker [31]
ASS1 OT4ZMG0Q Strong Biomarker [73]
BST1 OTAV5SE7 Strong Biomarker [74]
CUL4A OTTBV70J Strong Altered Expression [75]
EFEMP1 OTZVUOOB Strong Altered Expression [76]
EFNA1 OTU2NUA2 Strong Biomarker [77]
EIF6 OTEXMUED Strong Altered Expression [78]
GDE1 OTU6FSBF Strong Biomarker [79]
HAPLN1 OTXWR9TJ Strong Biomarker [80]
MINDY4 OTBZ2SZB Strong Altered Expression [24]
MT1B OTUA4FFH Strong Biomarker [31]
MT1E OTXJKU4Y Strong Biomarker [31]
MT1F OTZVUYG1 Strong Biomarker [31]
MT1G OTAV1OCR Strong Biomarker [31]
MT1H OT0MVBM6 Strong Biomarker [31]
MT1M OTVT8PLU Strong Biomarker [31]
MT1X OT9AKFVS Strong Biomarker [31]
PDPN OTBUV19I Strong Altered Expression [81]
PPP1R15A OTYG179K Strong Biomarker [82]
PUF60 OTG90DYF Strong Biomarker [83]
SETDB1 OTWVUA1B Strong Genetic Variation [84]
THY1 OTVONVTB Strong Altered Expression [85]
------------------------------------------------------------------------------------
⏷ Show the Full List of 65 DOT(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6837).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.J Thorac Oncol. 2013 May;8(5):644-53. doi: 10.1097/JTO.0b013e318287c224.
5 Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma.J Pathol. 2007 Mar;211(4):447-54. doi: 10.1002/path.2121.
6 Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma.J Thorac Oncol. 2019 Aug;14(8):1458-1471. doi: 10.1016/j.jtho.2019.03.029. Epub 2019 May 9.
7 Transcriptional over-expression of chloride intracellular channels 3 and 4 in malignant pleural mesothelioma.Comput Biol Chem. 2015 Dec;59 Pt A:111-6. doi: 10.1016/j.compbiolchem.2015.09.012. Epub 2015 Sep 28.
8 Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.J Thorac Oncol. 2016 Jan;11(1):94-107. doi: 10.1016/j.jtho.2015.09.004.
9 Second generation sequencing of the mesothelioma tumor genome.PLoS One. 2010 May 13;5(5):e10612. doi: 10.1371/journal.pone.0010612.
10 Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.Anticancer Res. 2015 Nov;35(11):6223-9.
11 EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.Oncogenesis. 2019 Sep 4;8(9):49. doi: 10.1038/s41389-019-0159-6.
12 Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.Oncologist. 2019 Jul;24(7):e510-e517. doi: 10.1634/theoncologist.2018-0501. Epub 2018 Nov 26.
13 Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.Int J Oncol. 2018 Nov;53(5):2034-2046. doi: 10.3892/ijo.2018.4555. Epub 2018 Sep 7.
14 CXCR4+FOXP3+CD25+ lymphocytes accumulate in CXCL12-expressing malignant pleural mesothelioma.Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):43-51. doi: 10.1177/039463200902200106.
15 Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.Int J Oncol. 2017 Mar;50(3):1044-1052. doi: 10.3892/ijo.2017.3870. Epub 2017 Feb 9.
16 Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma.Int J Oncol. 2016 Aug;49(2):448-56. doi: 10.3892/ijo.2016.3566. Epub 2016 Jun 7.
17 Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.PLoS One. 2017 Oct 2;12(10):e0185850. doi: 10.1371/journal.pone.0185850. eCollection 2017.
18 Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.Int J Nanomedicine. 2019 Jan 23;14:773-785. doi: 10.2147/IJN.S186344. eCollection 2019.
19 Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.Mod Pathol. 2020 Feb;33(2):235-244. doi: 10.1038/s41379-019-0309-6. Epub 2019 Jun 23.
20 Antiproliferative Activity of Pt(IV) Conjugates Containing the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Ketoprofen and Naproxen (?.Int J Mol Sci. 2019 Jun 24;20(12):3074. doi: 10.3390/ijms20123074.
21 NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet Oncol. 2018 Jun;19(6):799-811. doi: 10.1016/S1470-2045(18)30193-1. Epub 2018 May 9.
22 Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model.Cancer Sci. 2015 Oct;106(10):1296-302. doi: 10.1111/cas.12752. Epub 2015 Sep 19.
23 Genomic events associated with progression of pleural malignant mesothelioma.Int J Cancer. 2009 Feb 1;124(3):589-99. doi: 10.1002/ijc.23949.
24 Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report.Int J Mol Sci. 2018 Feb 28;19(3):685. doi: 10.3390/ijms19030685.
25 Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma.J Pathol. 2007 Mar;211(4):439-46. doi: 10.1002/path.2120.
26 Role of MIF/CD74 signaling pathway in the development of pleural mesothelioma.Oncotarget. 2016 Mar 8;7(10):11512-25. doi: 10.18632/oncotarget.7314.
27 Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.Lung Cancer. 2019 Nov;137:64-70. doi: 10.1016/j.lungcan.2019.09.010. Epub 2019 Sep 16.
28 Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2226-2231. doi: 10.1073/pnas.1818865116. Epub 2019 Jan 18.
29 MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.Mol Ther. 2019 Sep 4;27(9):1665-1680. doi: 10.1016/j.ymthe.2019.05.020. Epub 2019 Jun 4.
30 Detection of TGF- in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.Lung Cancer. 2020 Jan;139:124-132. doi: 10.1016/j.lungcan.2019.11.013. Epub 2019 Nov 18.
31 Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.Oncotarget. 2018 Apr 27;9(32):22254-22268. doi: 10.18632/oncotarget.24962. eCollection 2018 Apr 27.
32 The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.Cancer Chemother Pharmacol. 2018 Jan;81(1):1-15. doi: 10.1007/s00280-017-3473-8. Epub 2017 Nov 10.
33 Altered protease-activated receptor-1 expression and signaling in a malignant pleural mesothelioma cell line, NCI-H28, with homozygous deletion of the -catenin gene.PLoS One. 2014 Nov 3;9(11):e111550. doi: 10.1371/journal.pone.0111550. eCollection 2014.
34 Signal Transducer and Activator of Transcription 1 (STAT1) Knock-down Induces Apoptosis in Malignant Pleural Mesothelioma.Pathol Oncol Res. 2017 Jul;23(3):595-605. doi: 10.1007/s12253-016-0157-3. Epub 2016 Dec 16.
35 Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.Clin Cancer Res. 2016 Mar 1;22(5):1197-210. doi: 10.1158/1078-0432.CCR-14-3379. Epub 2015 Oct 12.
36 DNA methylation profiling of asbestos-treated MeT5A cell line reveals novel pathways implicated in asbestos response. Arch Toxicol. 2018 May;92(5):1785-1795.
37 Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.Oncotarget. 2016 Nov 22;7(47):76577-76589. doi: 10.18632/oncotarget.10428.
38 TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.Anticancer Res. 2010 Oct;30(10):4309-15.
39 Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma.PLoS One. 2011 Apr 1;6(4):e18232. doi: 10.1371/journal.pone.0018232.
40 MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.PLoS One. 2014 Sep 15;9(9):e105919. doi: 10.1371/journal.pone.0105919. eCollection 2014.
41 Wnt/IL-1/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.Int J Cancer. 2020 Jan 1;146(1):192-207. doi: 10.1002/ijc.32419. Epub 2019 Jun 4.
42 Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity.BMC Cancer. 2014 Apr 30;14:304. doi: 10.1186/1471-2407-14-304.
43 Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells.Oncogene. 2010 Apr 1;29(13):1941-51. doi: 10.1038/onc.2009.478. Epub 2010 Jan 18.
44 A STAT3-NFkB/DDIT3/CEBP axis modulates ALDH1A3 expression in chemoresistant cell subpopulations.Oncotarget. 2015 May 20;6(14):12637-53. doi: 10.18632/oncotarget.3703.
45 Computational genomic analysis of PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring survival in malignant pleural mesothelioma.Am J Physiol Lung Cell Mol Physiol. 2015 Oct 1;309(7):L677-86. doi: 10.1152/ajplung.00051.2015. Epub 2015 Aug 7.
46 High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes.Lung Cancer. 2019 Apr;130:35-41. doi: 10.1016/j.lungcan.2019.02.005. Epub 2019 Feb 7.
47 Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.Mol Cancer Ther. 2017 Aug;16(8):1693-1704. doi: 10.1158/1535-7163.MCT-16-0821. Epub 2017 May 3.
48 Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma.Lung Cancer. 2019 Sep;135:56-65. doi: 10.1016/j.lungcan.2019.07.011. Epub 2019 Jul 13.
49 Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status.Front Physiol. 2017 Mar 21;8:156. doi: 10.3389/fphys.2017.00156. eCollection 2017.
50 Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.Ann Diagn Pathol. 2015 Aug;19(4):193-7. doi: 10.1016/j.anndiagpath.2015.03.007. Epub 2015 Apr 14.
51 Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.Cancer Res. 2015 Jan 15;75(2):264-9. doi: 10.1158/0008-5472.CAN-14-1008. Epub 2014 Dec 8.
52 Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.BMC Cancer. 2019 Jan 30;19(1):108. doi: 10.1186/s12885-019-5314-0.
53 Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.Nat Genet. 2016 Apr;48(4):407-16. doi: 10.1038/ng.3520. Epub 2016 Feb 29.
54 Malignant pleural mesothelioma-targeted CREBBP/EP300 inhibitory protein 1 promoter system for gene therapy and virotherapy.Cancer Res. 2008 Sep 1;68(17):7120-9. doi: 10.1158/0008-5472.CAN-08-0047.
55 The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.Lung Cancer. 2014 Sep;85(3):465-71. doi: 10.1016/j.lungcan.2014.06.018. Epub 2014 Jun 30.
56 Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.J Thorac Oncol. 2019 Mar;14(3):527-539. doi: 10.1016/j.jtho.2018.10.163. Epub 2018 Nov 5.
57 Molecular deletion of 9p sequences in non-small cell lung cancer and malignant mesothelioma.Genes Chromosomes Cancer. 1993 May;7(1):47-53. doi: 10.1002/gcc.2870070108.
58 Epigenetic down-regulation of integrin 7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.J Pathol. 2015 Oct;237(2):203-14. doi: 10.1002/path.4567. Epub 2015 Jul 14.
59 Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma.Tumour Biol. 2012 Dec;33(6):2031-40. doi: 10.1007/s13277-012-0462-8. Epub 2012 Jul 27.
60 Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.Oncol Res. 2006;16(5):235-43. doi: 10.3727/000000006783981062.
61 Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma.Carcinogenesis. 2002 Jun;23(6):1017-24. doi: 10.1093/carcin/23.6.1017.
62 An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.Br J Cancer. 2018 Mar 20;118(6):e13. doi: 10.1038/bjc.2018.3. Epub 2018 Feb 13.
63 Expression of plakophilin 3 in diffuse malignant pleural mesothelioma.Histol Histopathol. 2018 Sep;33(9):995-1004. doi: 10.14670/HH-11-996. Epub 2018 May 3.
64 The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells.Cancer Res. 2009 Feb 15;69(4):1485-93. doi: 10.1158/0008-5472.CAN-08-3659. Epub 2009 Jan 27.
65 Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.Lung Cancer. 2019 Apr;130:187-193. doi: 10.1016/j.lungcan.2019.02.004. Epub 2019 Feb 27.
66 Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model.Sci Rep. 2016 Nov 11;6:36829. doi: 10.1038/srep36829.
67 Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.Eur J Cancer. 2012 May;48(7):1096-107. doi: 10.1016/j.ejca.2011.11.009. Epub 2011 Dec 10.
68 Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up.Lung Cancer. 2008 Mar;59(3):369-76. doi: 10.1016/j.lungcan.2007.08.035. Epub 2007 Oct 24.
69 L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray.Carcinogenesis. 2005 Jan;26(1):17-25. doi: 10.1093/carcin/bgh276. Epub 2004 Sep 24.
70 Data-driven information retrieval in heterogeneous collections of transcriptomics data links SIM2s to malignant pleural mesothelioma.Bioinformatics. 2012 Jan 15;28(2):246-53. doi: 10.1093/bioinformatics/btr634. Epub 2011 Nov 20.
71 Loss of C/EBP- LIP drives cisplatin resistance in malignant pleural mesothelioma.Lung Cancer. 2018 Jun;120:34-45. doi: 10.1016/j.lungcan.2018.03.022. Epub 2018 Mar 26.
72 Disulfiram suppresses growth of the malignant pleural mesothelioma cells in part by inducing apoptosis.PLoS One. 2014 Apr 1;9(4):e93711. doi: 10.1371/journal.pone.0093711. eCollection 2014.
73 Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.J Clin Oncol. 2017 Jun 1;35(16):1778-1785. doi: 10.1200/JCO.2016.71.3230. Epub 2017 Apr 7.
74 CD157: From immunoregulatory protein to potential therapeutic target.Immunol Lett. 2019 Jan;205:59-64. doi: 10.1016/j.imlet.2018.06.007. Epub 2018 Jun 21.
75 Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma.J Cell Mol Med. 2015 Oct;19(10):2385-96. doi: 10.1111/jcmm.12620. Epub 2015 Jul 27.
76 Biomarkers for malignant pleural mesothelioma: a meta-analysis.Carcinogenesis. 2019 Nov 25;40(11):1320-1331. doi: 10.1093/carcin/bgz103.
77 Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer.Int J Nanomedicine. 2013;8:4481-94. doi: 10.2147/IJN.S41782. Epub 2013 Nov 21.
78 Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo.Oncotarget. 2015 Nov 10;6(35):37471-85. doi: 10.18632/oncotarget.5462.
79 Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.Lancet Oncol. 2017 Oct;18(10):1386-1396. doi: 10.1016/S1470-2045(17)30621-6. Epub 2017 Sep 1.
80 Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma.Clin Cancer Res. 2009 Apr 15;15(8):2602-11. doi: 10.1158/1078-0432.CCR-08-2755. Epub 2009 Apr 7.
81 Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma.Cancer Sci. 2019 Feb;110(2):726-733. doi: 10.1111/cas.13895. Epub 2019 Jan 8.
82 Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma.Cancer Biol Ther. 2006 Jan;5(1):48-53. doi: 10.4161/cbt.5.1.2237. Epub 2006 Jan 12.
83 Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma. Cancer Sci. 2011 Jul;102(7):1366-73. doi: 10.1111/j.1349-7006.2011.01931.x. Epub 2011 May 9.
84 Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.Oncotarget. 2016 Feb 16;7(7):8321-31. doi: 10.18632/oncotarget.7032.
85 Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression.Front Oncol. 2018 Feb 23;8:40. doi: 10.3389/fonc.2018.00040. eCollection 2018.